Palatin Technologies (NYSE:PTN) Earns Hold Rating from Analysts at assumed coverage on shares of Palatin Technologies (NYSE:PTNGet Rating) in a report published on Thursday. The firm issued a hold rating on the stock.

Palatin Technologies Price Performance

Shares of PTN opened at $2.60 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.61 and a current ratio of 2.68. The firm has a market cap of $28.99 million, a PE ratio of -0.84 and a beta of 0.99. The firm’s 50 day moving average price is $3.54 and its 200 day moving average price is $3.22. Palatin Technologies has a twelve month low of $2.14 and a twelve month high of $13.00.

About Palatin Technologies

(Get Rating)

Palatin Technologies, Inc is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD).

Featured Articles

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with's FREE daily email newsletter.